Title![]() |
Intervention | NCT ID | Sponsor | Status |
---|---|---|---|---|
Radiation Therapy in Treating Patients With Prostate Cancer | 36.25 Gy IMRT, 51.6 Gy IMRT | NCT01434290 | Radiation Therapy Oncology Group | Active, not recruiting |
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer... | Laboratory Biomarker Analysis, Placebo Administration, Rilimogene Galvacirepvec | NCT02326805 | National Cancer Institute (NCI) | Active, not recruiting |
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection... | Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate | NCT03887702 | Southwest Oncology Group | Recruiting |
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients | Laboratory Biomarker Analysis, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine | NCT03036930 | National Cancer Institute (NCI) | Active, not recruiting |
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation | Pamidronate, Calcium and vitamin D | NCT02074631 | Masonic Cancer Center, University of Minnesota | Recruiting |
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast... | Endocrine therapy interruption | NCT02308085 | International Breast Cancer Study Group | Active, not recruiting |
Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-... | Denosumab, Salpingo-Oophorectomy | NCT03382574 | National Cancer Institute (NCI) | Recruiting |
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | Endoxifen Hydrochloride, Placebo Administration, Questionnaire Administration | NCT03317405 | National Cancer Institute (NCI) | Active, not recruiting |
Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk | Metformin, Placebo | NCT02028221 | University of Arizona | Active, not recruiting |
Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil | Donepezil 5 mg, Placebo | NCT02822573 | Wake Forest University Health Sciences | Active, not recruiting |
Why I Joined a Clinical Trial
I was very excited to participate in this particular trial offered through the Cancer Institute to hopefully improve my chemo induced neuropathy. In being part of this research, I consider it a privilege to give back to those doctors and nurses who gave so much to me during my cancer diagnosis and chemotherapy.